InvestSMART

Avecho Biotechnology Limited (ASX: AVE) - Announcements

Current share price for AVE : $0.015 0.002 (11.76%)+

ASX company news and announcements for Avecho Biotechnology Limited (AVE) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Avecho Biotechnology Limited (AVE) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Avecho Biotechnology Limited (AVE), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Avecho Biotechnology Limited (AVE)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$58 Response to ASX Price Query 21 Oct 2026 3:40PM $0.018 $0.015 fallen by 16.67%
$58 Avecho to present at the Canaccord Drug and Device Confe 13 Oct 2026 9:16AM $0.016 $0.015 fallen by 6.25%
$58 Avecho to present at the ASX SMIDcaps Conference 23 Sep 2026 9:01AM $0.022 $0.015 fallen by 31.82%
$58 Avecho enters final stage of Phase III insomnia trial 31 Aug 2026 9:15AM $0.023 $0.015 fallen by 34.78%
$58 Notification regarding unquoted securities - AVE 27 Aug 2026 4:53PM $0.025 $0.015 fallen by 40%
$58 Appendix 4D and Half-year Financial Report 26 Aug 2026 8:25AM $0.021 $0.015 fallen by 28.57%
$58 Avecho strengthens BD capability with senior appointment 24 Aug 2026 9:54AM $0.021 $0.015 fallen by 28.57%
$58 Small Holding Share Sale Facility Completion 12 Aug 2026 10:02AM $0.021 $0.015 fallen by 28.57%
$58 Japanese patent granted for CBD capsule 3 Aug 2026 9:48AM $0.019 $0.015 fallen by 21.05%
$58 June 2026 Quarterly Activities Report & Appendix 4C 29 Jul 2026 9:43AM $0.021 $0.015 fallen by 28.57%
$58 Application for quotation of securities - AVE 30 Jun 2026 4:06PM $0.024 $0.015 fallen by 37.50%
$58 Positive Phase III Interim Analysis Results Investor Webinar 24 Jun 2026 9:01AM $0.015 $0.015 fallen by 0%
$58 Positive interim results from Phase III insomnia program 24 Jun 2026 8:50AM $0.015 $0.015 fallen by 0%
$58 Phase III Interim Analysis Outcome Webinar 23 Jun 2026 9:19AM $0.015 $0.015 fallen by 0%
$58 Trading Halt 22 Jun 2026 8:31AM $0.015 $0.015 fallen by 0%
$58 Notification regarding unquoted securities - AVE 2 Jun 2026 4:24PM $0.012 $0.015 risen by 25%
$58 Notification of cessation of securities - AVE 1 Jun 2026 9:22AM $0.012 $0.015 risen by 25%
$58 Final Director's Interest Notice 1 Jun 2026 9:22AM $0.012 $0.015 risen by 25%
$58 Small Holding Share Sale Facility 27 May 2026 9:55AM $0.013 $0.015 risen by 15.38%
$58 2026 Annual General Meeting Results 26 May 2026 2:53PM $0.013 $0.015 risen by 15.38%
$58 Chair's Address and CEO Presentation 26 May 2026 11:38AM $0.013 $0.015 risen by 20%
$58 Resignation of Non-Executive Director 25 May 2026 4:00PM $0.012 $0.015 risen by 25%
$58 Investor Webinar Presentation 25 May 2026 10:24AM $0.012 $0.015 risen by 25%
$58 Receipt of Research & Development Tax Incentive 22 May 2026 9:41AM $0.012 $0.015 risen by 25%
$58 Avecho completes treatment for Phase III interim analysis 21 May 2026 10:16AM $0.013 $0.015 risen by 20%

1 - 25 of 319 results

Page 1 of 13

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.